Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mesoblast ( (MESO) ) has provided an update.
On December 17, 2025, Mesoblast Limited reported to the U.S. Securities and Exchange Commission that it had lodged an Appendix 3G with the Australian Securities Exchange, confirming the issue of 5 million unquoted warrants as part of a previously announced placement-linked financing. The new warrants, designated as a new class (Warrants 3) exercisable at A$2.50 per share and expiring on December 17, 2029, were issued as a commitment fee for access to a convertible note facility of up to US$50 million, which the company may draw on following shareholder approval at its 2025 AGM. Each warrant converts into one ordinary share, or in the case of American Depositary Receipts, 10 warrants convert into one ADR at an exercise price of US$16.25 per ADR, with 3 million of the warrants vesting only if Mesoblast exercises its option under the note facility. The issuance modestly increases Mesoblast’s unquoted securities and underscores its ongoing reliance on structured financing to support operations, with potential future dilution for shareholders if the warrants are exercised.
The most recent analyst rating on (MESO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score reflects a company with strong growth potential but significant financial challenges. The earnings call provided positive insights into market access and product launches, which are promising for future growth. However, financial performance and valuation concerns weigh down the score, with technical indicators suggesting caution due to overbought conditions.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is an Australia-incorporated biotechnology company listed on the ASX under the code MSB. The company develops and commercializes advanced cellular medicines, with its capital structure including a mix of quoted ordinary shares and various classes of unquoted options and warrants used to support its financing arrangements and strategic partnerships.
Average Trading Volume: 241,631
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.35B
Learn more about MESO stock on TipRanks’ Stock Analysis page.